IGF-1 Receptor/IGF1R Antibody (7G11): sc-81464

IGF-IR Antibody (7G11) is a mouse monoclonal IgG1 antibody that detects IGF-IR in mouse, rat, and human samples through western blotting (WB) and immunoprecipitation (IP). Anti-IGF-IR antibody (7G11) is available in a non-conjugated form, allowing for versatile applications in research. The insulin-like growth factor-I receptor (IGF-IR) plays a crucial role as a receptor tyrosine kinase, influencing a variety of cellular processes such as growth, survival, and differentiation. Located on the cell membrane, IGF-IR is activated by insulin-like growth factor-I (IGF-I), which triggers a cascade of intracellular signaling pathways vital for cellular responses to growth factors. IGF-IR′s ability to modulate cell proliferation and inhibit apoptosis is particularly important in cancer, as aberrant IGF-IR signaling can contribute to tumor growth and resistance to therapy. The human IGF-IR gene, located on chromosome 15q26.3, encodes a precursor protein that is cleaved into α and β subunits, which are essential for functional activity. Understanding IGF-IR structure and function is critical for developing targeted therapies in oncology and other diseases where growth factor signaling is dysregulated.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IGF-1 Receptor/IGF1R Antibody (7G11) References:

1. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane.  |  Song, RX., et al. 2004. Proc Natl Acad Sci U S A. 101: 2076-81. PMID: 14764897
2. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.  |  Mitsiades, CS., et al. 2004. Cancer Cell. 5: 221-30. PMID: 15050914
3. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.  |  Salatino, M., et al. 2004. Oncogene. 23: 5161-74. PMID: 15122317
4. IL-1beta impairs insulin-like growth factor i-induced differentiation and downstream activation signals of the insulin-like growth factor i receptor in myoblasts.  |  Broussard, SR., et al. 2004. J Immunol. 172: 7713-20. PMID: 15187154
5. Insulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells.  |  Hayashi, K., et al. 2004. J Biol Chem. 279: 40807-18. PMID: 15272025
6. Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis.  |  Shimizu, C., et al. 2004. Hum Pathol. 35: 1537-42. PMID: 15619214
7. Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.  |  Wu, J. and Yu, E. 2014. Cancer Metastasis Rev. 33: 607-17. PMID: 24414227
8. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.  |  Smith, TJ. and Janssen, JAMJL. 2019. Endocr Rev. 40: 236-267. PMID: 30215690
9. Insulin-like Growth Factor I Receptor: A Novel Target for Hepatocellular Carcinoma Gene Therapy.  |  Wang, L., et al. 2019. Mini Rev Med Chem. 19: 272-280. PMID: 30360707
10. Mechanism of insulin and IGF-I receptor activation and signal transduction specificity. Receptor dimer cross-linking, bell-shaped curves, and sustained versus transient signaling.  |  De Meyts, P., et al. 1995. Ann N Y Acad Sci. 766: 388-401. PMID: 7486684
11. Molecular defects of insulin/IGF-1 receptor transmembrane signaling.  |  Frattali, AL. and Pessin, JE. 1993. Ann N Y Acad Sci. 687: 77-89. PMID: 8323192
12. Insulin and IGF-I signaling through the insulin receptor substrate 1.  |  Keller, SR., et al. 1993. Mol Reprod Dev. 35: 346-51; discussion 351-2. PMID: 8398112

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-IGF-1 Receptor/IGF1R Antibody (7G11) has 48 citations in a variety of scientific publications.

Primary antibodies like Anti-IGF-1 Receptor/IGF1R Antibody (7G11) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

IGF-1 Receptor/IGF1R Antibody (7G11) Specifications

Alternate Product Name: IGF-1 Receptor

Product Clone Name: 7G11

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids:

Epitope Target: IGF-IR

Epitope Species: human

Product Reactivity/Detection: IGF-IR

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP

Vialing Information: Each vial contains 50 µg IgG₁ in 0.5 ml of PBS with < 0.1% sodium azide, 0.1% gelatin, PEG and sucrose

Research Citations: 48 citations in various scientific publications

Available Conjugates/Forms for IGF-1 Receptor/IGF1R Antibody (7G11): N/A

The preferred INSR/Insulin Receptor β antibody is INSR/Insulin Receptor β Antibody (CT-3): sc-57342.